Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Swiss-PO: A Web Tool for Personalised Oncology – Upcoming Updates
1
Mins
December 2023
Next-generation sequencing techniques enable rapid detection of mutations present in a patient’s tumour. The next step is to define…
Read more
1
Mins
12th November 2019
A Novel Affinity-Enhanced NY-ESO-1-Targeting TCR-Redirected T cell Transfer Exhibiting Early-Onset Cytokine Release Syndrome and Subsequent Tumour Responses in Synovial Sarcoma Patients
Adoptive transfer of T cell receptor (TCR)-redirected T cells has been reported to exhibit efficacy in some patients with melanoma and sarcoma…
2
Mins
12th November 2019
A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Nonresectable or Metastatic Soft Tissue Sarcomas Who are Not Candidates for Chemotherapy
Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis with a median survival of 12–14 months.1 First-line therapy consists…
2
Mins
12th November 2019
The Mutational Signature of Spontaneously Developing Tumours in MLH1-/- Mice - Potential Consequences for Immunotherapeutic Approaches
Mismatch repair-deficient (MMR-D) tumours exemplify the prototypic hypermutator phenotype. Owing to the high mutation rates, many neo-antigens…
1
Mins
12th November 2019
The 2016-2019 ImmunoTOX Assessment Board Report: Results from a Descriptive Real-Life Study of a Collaborative Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors
Although immunotherapy is better tolerated globally than chemotherapy, immune checkpoint inhibitors may be associated with immune-related…
2
Mins
12th November 2019
Measuring the Cancer Burden in Europe: the European Cancer Information System (ECIS)
Cancer is the second leading cause of mortality in European Union (EU) Member States,1 with more than 1.4 million deaths…
1
Mins
12th November 2019
Phase I Combination Dose-Finding and Phase II Expansion Cohorts of Lenvatinib with Etoposide and Ifosfamide in Patients Aged 2 to ≤25 Years with Relapsed or Refractory Osteosarcoma
Osteosarcoma is the most common primary bone tumour in adolescents and young adults, with no survival improvement in the last few decades…
2
Mins
6th December 2018
First In-Human Study with GSK3359609, an Inducible T cell Costimulator Receptor Agonist in Patients with Advanced, Solid Tumours: Preliminary Results from INDUCE-1
Inducible T cell costimulator (ICOS), a member of the CD28/B7 receptor superfamily, is expressed on T cells after T cell receptor engagement with cognate…
1
Mins
6th December 2018
Preliminary Safety, Efficacy, and Pharmacokinetic and Pharmacodynamic Characterisation from GARNET, a Phase I Clinical Trial of the Anti-PD-1 Monoclonal Antibody TSR-042 in Patients with Recurrent or Advanced Microsatellite Instability-High Endometrial Cancer
At the European Society for Medical Oncology (ESMO) 2018 Congress, data from the ongoing Phase I clinical trial of the anti-programmed death…
Loading posts...
« Previous
1
2
3
4
5
6
Next »